SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE

The following table summarizes the shares of common stock that were potentially issuable but were excluded from the computation of diluted net loss per share for the three months ended March 31, 2024 and 2023 as such shares would have had an anti-dilutive effect:

	As of March 31,
	2024		2023
Stock options (a)		90,833		146,191
Warrants (b)		16,725		16,725
Unvested restricted stock		193,217		181,887

(a)	Shares underlying stock options assumed pursuant to the merger agreement with Precision Healing, Inc. (“Precision Healing”) in April 2022.
(b)	Shares underlying warrants assumed pursuant to the merger agreement with Precision Healing in April 2022.

SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES

Revenue streams from product sales and royalties are summarized below for the three months ended March 31, 2024 and 2023.

	Three Months Ended
	March 31,
	2024		2023
Soft tissue repair products	$	16,082,292	$	12,872,481
Bone fusion products		2,454,346		2,599,186
Royalty revenue		-		50,250
Total Net Revenue	$	18,536,638	$	15,521,917

SCHEDULE OF PROPERTY AND EQUIPMENT

	Useful	March 31,			December 31,
	Life	2024			2023
Computers	3-5 years	$	215,500		$	194,788
Office equipment	3-7 years		214,190			201,785
Furniture and fixtures	5-10 years		304,338			304,338
Leasehold improvements	2-5 years		166,871			134,170
Internal use software	5 years		1,618,999			1,618,999
			2,519,898			2,454,080
Less accumulated depreciation			(1,329,093	)		(1,196,124	)
Property and equipment, net		$	1,190,805		$	1,257,956

SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION

Balance at December 31, 2023	$	3,823,001
Changes in fair value of earnout liabilities		(65,678	)
Balance at March 31, 2024	$	3,757,323